KYMRIAH Market Summary

Key Factors Driving KYMRIAH Growth

1. Multiple approved indications broaden the addressable patient population: KYMRIAH is a CD19-directed autologous CAR-T therapy approved in the U.S. for patients up to 25 years with relapsed/refractory B-cell precursor ALL, adults with relapsed/refractory large B-cell lymphoma after ≥2 systemic therapies, and adults with relapsed/refractory follicular lymphoma after ≥2 lines of systemic therapy. The addition of follicular lymphoma to its label provides an important diversification opportunity beyond ALL and DLBCL.

2. Durable efficacy in pediatric and young-adult B-ALL supports continued adoption: Long-term ELIANA data published in 2026 showed that among 79 pediatric and young-adult patients, the estimated 5-year relapse-free survival among responders was 47.3%, while 5-year overall survival was 55.0%; when subsequent stem-cell transplantation was not treated as a competing event, the corresponding estimates were 51.0% and 62.4%. No new or unexpected adverse events were reported. These long-term outcomes support KYMRIAH's role as a potentially definitive one-time treatment for heavily pretreated B-ALL.

3. Strong and durable activity in relapsed/refractory follicular lymphoma: The ELARA Phase II study provides a significant growth opportunity in FL. At approximately 29 months of follow-up, KYMRIAH achieved an 86.2% overall response rate and 68.1% complete response rate; estimated 24-month progression-free survival, duration of response and overall survival were 57.4%, 66.4% and 87.7%, respectively. Durable responses in heavily pretreated and high-risk patients can support continued adoption of CAR-T in later-line FL.

4. Very long-term lymphoma-remission data strengthen the value proposition of a single infusion: A 2026 NEJM study following patients treated with tisagenlecleucel for a median of 10.1 years reported that no relapses occurred beyond 5.4 years in the evaluated cohort. Ten-year lymphoma-free survival was 32% for large B-cell lymphoma and 47% for follicular lymphoma. Although the study was small (38 patients) and should not be generalized to all KYMRIAH-treated patients, such evidence reinforces the possibility of long-term treatment-free remission after a single CAR-T infusion.

5. Expansion of CAR-T access and manufacturing efficiency could increase utilization: Manufacturing time and treatment-center capacity remain important constraints for autologous CAR-T therapies. Novartis has been developing its T-Charge manufacturing platform, designed to reduce ex-vivo cell expansion and potentially shorten manufacturing turnaround. Novartis has targeted approximately 10 days or less for future CAR-T products in the US, compared with approximately 3–4 weeks for current KYMRIAH manufacturing. Faster manufacturing could potentially allow more patients to receive CAR-T before clinical deterioration, although T-Charge is not the current commercial manufacturing process for KYMRIAH.

KYMRIAH Recent Developments

In March 2026, The FDA issued an Untitled Letter to Novartis citing promotional materials for KYMRIAH. The agency declared that digital content and marketing sales aids made false or misleading claims regarding Progression-Free Survival (PFS) and Overall Survival (OS) benefits. The FDA highlighted that because the underlying trials (ELARA and ELIANA) were single-arm studies without appropriate comparators, time-to-event endpoints are uninterpretable and cannot be attributed strictly to KYMRIAH.

“KYMRIAH Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of KYMRIAH for approved indication like Diffuse large B cell lymphoma, Follicular lymphoma, and Precursor B-cell lymphoblastic leukaemia-lymphoma; as well as potential indication like Multiple myeloma and Non-Hodgkin’s lymphoma in the 7MM. A detailed picture of KYMRIAH’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the KYMRIAH for approved and potential indications. The KYMRIAH market report provides insights about KYMRIAH’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current KYMRIAH performance, future market assessments inclusive of the KYMRIAH market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of KYMRIAH sales forecasts, along with factors driving its market.

KYMRIAH Drug Summary

KYMRIAH is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Novartis for the treatment of certain B-cell malignancies. It is a genetically modified cellular immunotherapy that targets CD19, an antigen expressed on the surface of malignant and normal B cells. The treatment involves collecting the patient's own T cells through leukapheresis, genetically modifying them using a lentiviral vector to express a CD19-directed CAR, expanding the engineered cells ex vivo, and reinfusing them into the patient following lymphodepleting chemotherapy. Once administered, tisagenlecleucel recognizes CD19-expressing cancer cells, activating the patient's modified T cells to proliferate and induce targeted tumor-cell destruction through cytotoxic immune mechanisms. KYMRIAH is administered as a single intravenous infusion and is approved for eligible pediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse, as well as adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy and adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, subject to applicable regulatory approvals. Its therapeutic potential is supported by durable responses in selected patients with relapsed or refractory hematologic malignancies. However, treatment is associated with potentially serious adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), prolonged cytopenias, infections, and hypogammaglobulinemia, requiring specialized clinical monitoring and supportive care. KYMRIAH represents a significant advancement in personalized oncology by harnessing genetically engineered autologous T cells to provide targeted immunotherapeutic activity against CD19-positive B-cell cancers. The report provides KYMRIAH’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the KYMRIAH Market Report

The report provides insights into:

• A comprehensive product overview including the KYMRIAH MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma, Follicular lymphoma, and Precursor B-cell lymphoblastic leukaemia-lymphoma; as well as potential indication like Multiple myeloma and Non-Hodgkin’s lymphoma.
• Elaborated details on KYMRIAH regulatory milestones and other development activities have been provided in KYMRIAH market report.
• The report also highlights KYMRIAH‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The KYMRIAH market report also covers the patents information, generic entry and impact on cost cut.
• The KYMRIAH market report contains current and forecasted KYMRIAH sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The KYMRIAH market report also features the SWOT analysis with analyst views for KYMRIAH in approved and potential indications.

Methodology

The KYMRIAH market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

KYMRIAH Analytical Perspective by DelveInsight

• In-depth KYMRIAH Market Assessment

This KYMRIAH sales market forecast report provides a detailed market assessment of KYMRIAH for approved indication like Diffuse large B cell lymphoma, Follicular lymphoma, and Precursor B-cell lymphoblastic leukaemia-lymphoma; as well as potential indication like Multiple myeloma and Non-Hodgkin’s lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted KYMRIAH sales data uptil 2034.

• KYMRIAH Clinical Assessment

The KYMRIAH market report provides the clinical trials information of KYMRIAH for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

KYMRIAH Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

KYMRIAH Market Potential & Revenue Forecast

• Projected market size for the KYMRIAH and its key indications
• Estimated KYMRIAH sales potential (KYMRIAH peak sales forecasts)
• KYMRIAH Pricing strategies and reimbursement landscape

KYMRIAH Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• KYMRIAH Market positioning compared to existing treatments
• KYMRIAH Strengths & weaknesses relative to competitors

KYMRIAH Regulatory & Commercial Milestones

• KYMRIAH Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

KYMRIAH Clinical Differentiation

• KYMRIAH Efficacy & safety advantages over existing drugs
• KYMRIAH Unique selling points

KYMRIAH Market Report Highlights

• In the coming years, the KYMRIAH market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The KYMRIAH companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence KYMRIAH’s dominance.
• Other emerging products for Diffuse large B cell lymphoma, Follicular lymphoma, and Precursor B-cell lymphoblastic leukaemia-lymphoma; as well as potential indication like Multiple myeloma and Non-Hodgkin’s lymphoma are expected to give tough market competition to KYMRIAH and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of KYMRIAH in approved and potential indications.
• Analyse KYMRIAH cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted KYMRIAH sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of KYMRIAH in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of KYMRIAH? How strong is KYMRIAH’s clinical and commercial performance?
• What is KYMRIAH’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma, Follicular lymphoma, and Precursor B-cell lymphoblastic leukaemia-lymphoma; as well as potential indication like Multiple myeloma and Non-Hodgkin’s lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the KYMRIAH Manufacturers?
• What are the key designations that have been granted to KYMRIAH for approved and potential indications? How are they going to impact KYMRIAH’s penetration in various geographies?
• What is the current and forecasted KYMRIAH market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of KYMRIAH in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to KYMRIAH for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is KYMRIAH? What is the duration of therapy and what are the geographical variations in cost per patient?